Voriconazole, a powerful antifungal used mainly against serious Aspergillus infections, carries a wide range of side effects that touch nearly every organ system. The three most commonly flagged concerns are liver damage, skin reactions, and visual disturbances, though the full list extends to bone pain, heart rhythm changes, neurological problems, and hormonal disruption.1PubMed. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole Many of these side effects track with drug levels in the blood, which is why monitoring those levels has become a central part of using voriconazole safely.
Visual Disturbances
One of the most distinctive side effects of voriconazole is transient visual disturbance, sometimes called “enhanced light perception.” People describe seeing halos around lights, experiencing blurred vision, altered color perception, or unusual brightness, especially in the first hours after a dose. These episodes are typically brief, lasting around 30 minutes, and tend to improve or disappear over the course of treatment. In one study of hospitalized patients, about 12% reported visual disturbance, while a larger retrospective analysis found visual complaints in roughly 5% of those treated.2International Journal of Infectious Diseases. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients
Research in animal models has pinpointed the mechanism with reasonable confidence. Voriconazole interferes with a specific class of cells in the retina called ON-bipolar cells, which are responsible for processing signals when light hits the eye. The drug blocks ion channels (TRPM1 and the closely related TRPM3) that these cells need to relay information about light and dark. This disruption is selective and reversible, which explains why vision returns to normal once the drug clears the system.3PubMed Central. Voriconazole, an antifungal triazol that causes visual side effects, is an inhibitor of TRPM1 and TRPM3 channels Primate studies confirmed the same pattern: ON-bipolar cells in both the rod and cone pathways were selectively and reversibly affected, matching what patients describe.4Investigative Ophthalmology & Visual Science. Mechanism of Voriconazole-Induced Transient Visual Disturbance: Reversible Dysfunction of Retinal ON-Bipolar Cells in Monkeys
While these visual changes are alarming, they are generally considered benign and not a reason to stop the drug on their own. However, patients should be warned before starting treatment so the symptoms do not trigger unnecessary panic, particularly since the visual disturbances often strike at night or in low-light settings and can be confused with something more serious.
Liver Injury
Liver toxicity is probably the side effect that clinicians worry about most with voriconazole, because it can force early discontinuation of a drug the patient genuinely needs. A large retrospective study found that liver injury occurred in about 11% of patients, roughly split between a pattern dominated by liver cell damage and one dominated by bile flow disruption, with a smaller fraction showing both.5PubMed Central. Voriconazole-induced liver injury: incidence patterns and risk factors in a retrospective cohort In another study of 25 patients, abnormal liver function tests were the single most common adverse event, appearing in nearly half.6International Journal of Infectious Diseases. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients
Hepatotoxicity generally shows up as rising liver enzyme levels on blood tests, sometimes accompanied by elevated bilirubin or alkaline phosphatase. Most cases are caught through routine lab monitoring before the patient feels symptoms. However, in more severe presentations, patients can develop jaundice, nausea, or abdominal pain. Drug levels in the blood play an important role here: a meta-analysis found that trough concentrations above 3.0 mg/L carry a clearly increased risk of moderate to severe liver damage.7Journal of Antimicrobial Chemotherapy. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis Researchers are also exploring whether blood markers like glycocholate, a bile acid, could help predict liver problems earlier than traditional measures alone.8PubMed. Enhancing the identification of voriconazole-associated hepatotoxicity by targeted metabolomics
Skin Reactions and Skin Cancer Risk
Voriconazole can make your skin extremely sensitive to sunlight. This photosensitivity can appear as severe sunburn after modest sun exposure, blistering, or a rash on sun-exposed areas. The exact cause is still not fully settled, but two leading theories exist. One is that the drug’s primary breakdown product, voriconazole N-oxide, absorbs UV light and acts as the irritant. The other is that voriconazole raises blood levels of retinol (a form of vitamin A) by blocking the liver enzymes that normally break it down, and elevated retinol has been linked to sun sensitivity on its own.9PubMed Central. Voriconazole-Induced Photosensitivity in Children: A Case Report and Literature Review Both mechanisms may contribute simultaneously.
The more serious concern is what happens with prolonged use. Photosensitivity can be a stepping stone to actual skin cancer, particularly squamous cell carcinoma. This risk is best documented in organ transplant recipients, who are already immunosuppressed and therefore more vulnerable to skin malignancies. Voriconazole is now recognized as an independent risk factor for skin cancer in lung transplant patients.10PubMed Central. Voriconazole-Associated Cutaneous Malignancy: A Literature Review on Photocarcinogenesis in Organ Transplant Recipients A study of lung transplant recipients in the United States found that skin cancer risk climbed steadily with longer voriconazole exposure: roughly tripled after 15 months of use compared to patients who had never taken the drug.11JAMA Dermatology. Voriconazole and the Risk of Keratinocyte Carcinomas Among Lung Transplant Recipients in the United States The cancers that develop tend to be more aggressive and appear in multiple sites at once, which is a departure from typical squamous cell carcinoma behavior.12PubMed. Adverse effects of voriconazole: Over a decade of use
The practical takeaway: anyone on long-term voriconazole, especially transplant recipients, should use aggressive sun protection (high-SPF sunscreen, protective clothing, shade) and get regular skin checks by a dermatologist. If photosensitivity develops, switching to an alternative antifungal is often advisable when the infection allows it.
Neurological and Psychiatric Effects
Beyond the visual disturbances discussed earlier, voriconazole can cause a range of nervous system problems. These include hallucinations, confusion, agitation, encephalopathy (a general term for brain dysfunction), and peripheral neuropathy (tingling or numbness in the hands and feet). In a retrospective study of 165 patients, central nervous system toxicity of some kind occurred in about one in five, with the median onset around six days after starting the drug.13PubMed Central. Central Nervous System Toxicity of Voriconazole: Risk Factors and Threshold – A Retrospective Cohort Study
Drug levels are a strong predictor of these problems. That same study identified a threshold trough concentration of about 4.85 mg/L: patients above this cutoff had roughly three times the rate of nervous system toxicity compared to those below it.14PubMed Central. Central Nervous System Toxicity of Voriconazole: Risk Factors and Threshold – A Retrospective Cohort Study A broader meta-analysis set the neurotoxicity threshold at 4.0 mg/L.15Journal of Antimicrobial Chemotherapy. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis The specific number may vary somewhat with the population studied, but the overall message is clear: neuropsychiatric symptoms should prompt a check of drug levels, and dose reduction usually resolves them.
Bone Pain and Fluoride Toxicity
Voriconazole contains fluorine atoms in its molecular structure, and long-term use leads to elevated fluoride levels in the blood. The consequence is periostitis, an inflammation of the tissue that wraps around bones, causing widespread aching bone pain that can be debilitating. This side effect surfaces primarily in patients on high doses or prolonged courses, and it has been described mainly in transplant and other immunocompromised populations.16PubMed Central. Voriconazole-associated periostitis: Pathophysiology, risk factors, clinical manifestations, diagnosis, and management
Patients typically develop diffuse bony pains along with elevated alkaline phosphatase and elevated plasma fluoride levels. Imaging studies can reveal characteristic changes around the bones consistent with periostitis.17PubMed. Spectrum of Voriconazole-Induced Periostitis With Review of the Differential Diagnosis A study comparing patients with and without periostitis found that blood fluoride levels, alkaline phosphatase, and both daily and cumulative voriconazole dose were all significantly higher in the periostitis group. Reassuringly, stopping or reducing the dose led to pain improvement in about 89% of patients.18PubMed Central. Plasma Fluoride Level as a Predictor of Voriconazole-Induced Periostitis in Patients With Skeletal Pain This is one of those side effects that is easy to miss if clinicians are not specifically looking for it. Unexplained bone pain in a patient on long-term voriconazole should raise a red flag.
Heart Rhythm Changes
Voriconazole can prolong the QT interval, a measure of the heart’s electrical recovery time between beats. When the QT interval stretches too long, it increases the risk of dangerous arrhythmias. A study of cancer patients found that the average QTc during voriconazole therapy was significantly longer than off therapy. More concretely, about 28% of patients experienced a prolongation of 60 milliseconds or more, which is considered clinically meaningful.19PubMed. Voriconazole-induced QT prolongation among hemato-oncologic patients: clinical characteristics and risk factors Patients who already had a borderline-long QT at baseline or low potassium levels were at the highest risk. This is relevant because voriconazole also has a tendency to lower potassium, creating a compounding problem.
Electrolyte and Endocrine Disruptions
Voriconazole can cause drops in both potassium and sodium levels. Hypokalemia (low potassium) occurred in about 18% of patients in one study, and most cases appeared within the first two weeks of treatment. Women, patients receiving the drug intravenously, and patients also taking antibiotics were at higher risk.20PubMed. Hypokalemia and Hyponatremia in Adult Patients Receiving Voriconazole Therapeutic Drug Monitoring Severe potassium depletion can lead to muscle cramps, weakness, and in rare cases, rhabdomyolysis, where muscle tissue breaks down and releases proteins that can damage the kidneys.21PubMed Central. Voriconazole- induced severe hypokalemic rhabdomyolysis: A case report
Because voriconazole is a potent inhibitor of certain liver enzymes, it can also interfere with hormone production. The same enzyme pathway it uses to kill fungi overlaps with the pathway the body uses to manufacture cortisol and other steroid hormones. This means voriconazole can suppress the adrenal glands, leading to adrenal insufficiency, a condition where the body cannot produce enough cortisol on its own.22PubMed Central. Voriconazole Usage, An Atypical Cause Of Primary Adrenal Insufficiency Other hormonal effects reported include gynecomastia (breast tissue enlargement in men) and disrupted gonadal function, all traceable to that same enzyme inhibition.23F1000Research. Case Report: Voriconazole induced refractory hyperkalemia and adrenal insufficiency These endocrine side effects are probably underrecognized because they mimic symptoms of the underlying illness or its other treatments.
Why Drug Levels Vary So Much Between People
A recurring theme across almost every voriconazole side effect is the connection to drug levels. What makes this tricky is that the same standard dose can produce wildly different blood concentrations from one person to the next. A major driver of this variability is genetic differences in CYP2C19, a liver enzyme responsible for breaking down voriconazole. People who carry gene variants that make this enzyme work faster (ultrarapid metabolizers) tend to have low drug levels and may not achieve therapeutic concentrations. People with variants that slow the enzyme down (poor metabolizers) accumulate the drug and face a higher risk of toxicity at standard doses.24PubMed Central. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy
These genetic differences are not evenly distributed across populations. The poor-metabolizer variant is more common in certain ethnic groups, which contributes to the observation that Asian patients may face a higher risk of liver toxicity at a given trough concentration.25Journal of Antimicrobial Chemotherapy. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis Formal pharmacogenetic guidelines now exist recommending that clinicians consider CYP2C19 genotyping before starting voriconazole, and that poor metabolizers receive a lower dose or an alternative drug.26PubMed Central. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy
The Role of Therapeutic Drug Monitoring
Given that side effects track so closely with blood levels, routine measurement of trough concentrations has become a cornerstone of safe voriconazole use. The general targets that have emerged from the literature are a trough of at least 0.5 mg/L for effectiveness, with the ceiling set at around 3.0 mg/L to avoid liver toxicity and 4.0 mg/L to avoid neurotoxicity.27Journal of Antimicrobial Chemotherapy. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis
A randomized controlled trial tested whether formal drug monitoring changed outcomes. While the overall rate of adverse events was similar whether or not levels were monitored (42% in both groups), the rate of actually having to stop voriconazole because of side effects dropped substantially with monitoring: 4% versus 17%.28Clinical Infectious Diseases. The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial That difference matters a lot when the patient has a life-threatening infection and switching antifungals is not straightforward.
Drug Interactions That Amplify the Problem
Voriconazole is metabolized through liver enzymes and is itself a potent inhibitor of several of them. This creates a two-way problem: other drugs can raise or lower voriconazole levels, and voriconazole can dramatically raise levels of other drugs. The most clinically consequential interaction is with immunosuppressants like tacrolimus and cyclosporine, which are used in nearly every organ transplant recipient. In one documented case, starting voriconazole caused such a dramatic spike in tacrolimus levels that tacrolimus had to be temporarily stopped entirely, because even the manufacturer’s recommended dose reduction was not enough to keep levels safe.29PubMed. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient
This interaction is especially important because transplant patients are among the most frequent users of long-term voriconazole. They are on narrow-therapeutic-window immunosuppressants that can cause kidney damage or infection if levels swing too far in either direction. Close monitoring of both voriconazole and the immunosuppressant is essential whenever the two are used together.
How Voriconazole Compares to Newer Alternatives
Isavuconazole, a newer antifungal in the same class, has been positioned as a potentially better-tolerated option. In the large SECURE trial, which compared the two head-to-head for invasive mold infections, both drugs performed similarly for effectiveness, but patients on isavuconazole had significantly fewer eye problems (15% versus 27%), liver and bile duct disorders (9% versus 16%), and skin reactions (33% versus 42%). Drug-related adverse events overall were reported in 42% of the isavuconazole group versus 60% of the voriconazole group.30The Lancet. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial A meta-analysis confirmed the overall pattern: isavuconazole had a roughly 30% lower rate of drug-related adverse events and a meaningfully lower rate of discontinuation due to side effects.31PubMed Central. Efficacy and safety of isavuconazole versus voriconazole for the treatment of invasive fungal infections: a meta-analysis with trial sequential analysis
That said, voriconazole remains the more established drug with decades of clinical experience, and not every patient or infection type has been studied with isavuconazole. A retrospective comparison in chronic pulmonary aspergillosis found that 86% of voriconazole patients experienced adverse events versus 60% on isavuconazole, though once adverse events did occur, the rates of drug discontinuation were similar between the two.32PubMed. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events For patients who cannot tolerate voriconazole, isavuconazole is an increasingly attractive option.
Special Populations
Children metabolize voriconazole differently from adults. At the same weight-based dose, children achieve substantially lower drug levels, which means they often need higher doses per kilogram to reach the same target range. A pediatric pharmacokinetic study found that the safety profile in children was broadly similar to adults, with elevated liver enzymes being the most common treatment-related adverse event, but no clear correlation between drug exposure and adverse events was found in the pediatric group.33PubMed Central. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children Photosensitivity has also been reported in children, and the same aggressive sun protection recommendations apply.
Voriconazole is contraindicated in pregnancy. Animal studies have shown skeletal abnormalities in the offspring of mice given the drug during gestation, including reduced skull ossification, extra ribs, and missing bone in the fingers and toes, particularly at higher doses.34PubMed. Teratogenic effects of voriconazole (anti-fungal drug) on Swiss albino mice No controlled human data exist for obvious ethical reasons, but the animal evidence was sufficient for regulatory agencies to classify voriconazole as a drug that should not be used in pregnant women unless the benefit clearly outweighs the risk.
The IV Formulation and Kidney Concerns
The intravenous form of voriconazole is dissolved using a carrier molecule called sulfobutylether-beta-cyclodextrin (SBECD). This excipient is eliminated through the kidneys, and in patients with impaired kidney function, it accumulates in the blood. Early concerns were raised that SBECD itself might damage the kidneys, which led to the recommendation to avoid the IV formulation in patients with significant kidney impairment and use oral voriconazole instead. Subsequent human studies, including work in volunteers with kidney dysfunction, showed that while SBECD levels do accumulate, there were no harmful effects on kidney function specifically attributable to the carrier molecule.35PubMed. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD) Monitoring kidney function during IV therapy is still standard practice, but the fear of direct SBECD kidney toxicity appears to have been overstated.
This remains a common source of confusion in clinical practice. Clinicians sometimes hesitate to give IV voriconazole to patients with kidney problems even when the oral form is not feasible, such as in critically ill patients who cannot swallow. In those situations, the evidence suggests that IV voriconazole can be used with appropriate monitoring of creatinine levels, rather than being automatically ruled out.